Vista, CA

Moradi MD

Cutis Laxa

Deoxycholic acid

AGN-151586

OnabotulinumtoxinA

AbbVie

Allergan

Galderma

Kythera Biopharmaceuticals

Recros Medica

Amir Moradi MD, MBA

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Single Center, Double Blind, Placebo- Controlled Study of 20 subjects with 10 active drug/10 placebo

Standardized baseline/pre-treatments and follow-up images will be taken.

Subjects will receive injection of either study drug or placebo to the Depressor Anguli Oris. Follow ups will occur at 2 weeks, 4 weeks, and 12 weeks.

Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris

Moradi MD | Vista, CA

Site insights

Work at this site?

Active trials

Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris

Trial sponsors